MindWalk Holdings Corp. (NASDAQ:HYFT) Given Average Recommendation of "Hold" by Analysts

Key Points

• Analyst sentiment is mixed: Five firms give MindWalk an average “Hold” rating, with two sell, two buy and one strong-buy ratings. The average 12-month price target is $5.00, versus a recent share price of $1.33.
• Recent results missed expectations: MindWalk reported a quarterly loss of $0.06 per share, worse than the consensus loss estimate of $0.05, on revenue of $3.03 million. Analysts expect a full-year loss of $0.21 per share.
• Several institutional investors increased their positions, but institutional ownership remains limited at 6.7%. The stock has traded between $0.99 and $3.25 over the past year and has a market capitalization of approximately $62.1 million.

MindWalk Holdings Corp. (NASDAQ:HYFT - Get Free Report) has received a consensus recommendation of "Hold" from the five research firms that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, two have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $5.00.

Several research firms have issued reports on HYFT. Weiss Ratings reiterated a "sell (e+)" rating on shares of MindWalk in a research report on Wednesday, July 15th. Wall Street Zen raised MindWalk from a "sell" rating to a "hold" rating in a report on Saturday. HC Wainwright restated a "buy" rating on shares of MindWalk in a research note on Monday, July 20th. Finally, Zacks Research lowered MindWalk from a "hold" rating to a "strong sell" rating in a report on Tuesday, July 28th.

Institutional Investors Weigh In On MindWalk

Several institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can grew its stake in shares of MindWalk by 81.0% during the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company's stock worth $100,000 after purchasing an additional 24,500 shares during the period. Renaissance Technologies LLC increased its holdings in shares of MindWalk by 8.4% in the 4th quarter. Renaissance Technologies LLC now owns 239,080 shares of the company's stock valued at $435,000 after purchasing an additional 18,600 shares in the last quarter. Jane Street Group LLC lifted its stake in shares of MindWalk by 147.3% in the fourth quarter. Jane Street Group LLC now owns 161,202 shares of the company's stock valued at $293,000 after purchasing an additional 96,018 shares during the period. Bridgeway Capital Management LLC acquired a new stake in shares of MindWalk in the fourth quarter valued at about $91,000. Finally, XTX Topco Ltd boosted its holdings in MindWalk by 118.6% during the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company's stock worth $149,000 after buying an additional 44,331 shares in the last quarter. 6.70% of the stock is currently owned by hedge funds and other institutional investors.

MindWalk Price Performance

MindWalk stock opened at $1.33 on Wednesday. MindWalk has a 12 month low of $0.99 and a 12 month high of $3.25. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.80 and a quick ratio of 2.72. The business has a 50 day simple moving average of $1.45 and a 200-day simple moving average of $1.38. The stock has a market capitalization of $62.12 million, a PE ratio of -6.05 and a beta of 0.84.

MindWalk (NASDAQ:HYFT - Get Free Report) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The company had revenue of $3.03 million for the quarter. MindWalk had a negative return on equity of 92.61% and a negative net margin of 89.65%. Equities analysts predict that MindWalk will post -0.21 earnings per share for the current year.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source